Top Globe News – Lifestyle
Author:
JenaValve Technology, Inc.
JenaValve Appoints Dave Haan as Vice President of Clinical Affairs
May 12, 2026
JenaValve Announces the Start of Commercialization of the Trilogy® Transcatheter Heart Valve System in the United States – the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR)
April 1, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
March 18, 2026